Ann: ResApp Grants Option to Consumer Health Division of Sanofi, page-265

Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #

First 265 Last

Share
Profile

Follow
.@#.

665 Posts.

75

05/09/22

19:14

Post #: 63529486
Share

Originally posted by .@#.: ↑

I suppose there's only so much can be divulged as being fact when the collaboration has just begun, but we can speculate.

I had a run through @Phantom1 's content tonight and here's a few observations.

Firstly, I really appreciate the upfront and ongoing disclosure that he/she has an association with some of the RAP research; what capacity I don't know, but good to know.

Secondly, and I'm sorry to imply a link here if there isn't one, but contributions tend to be at times when we're looking for clarity. Like today.

Looking back, Phantom posted about the ERS International Conference in Spain (Sept/Oct '19) on September 5. Our participation in Creaosphere ws announced October 4. On October 23, Phantom posted about a paper out of WA and our tech's capacity to replicate (?) the Pulmonary Score results in asthma. This was also day one of Creaosphere.

Today an mou of sorts with Sanofi, with their integrated health platform (ongoing monitoring).

Joining the dots to me implies perhaps an integrated virtual asthma monitoring and treatment solution.

It's only an opinion and I'm happy to be corrected if I'm wrong.

Would be cool though...

Expand

...

"PASADENA, Calif., September 01, 2022--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:European Respiratory Society (ERS) International Congress 2022 – September 4-6, 2022Title: Silencing MMP7 expression with a lung-targeted RNAi molecule limits fibrosis and preserves pulmonary function in bleomycin-injured ratsPresenter: Erik Bush, Ph.D., Group Vice President, Biology, Arrowhead Pharmaceuticals".

https://au.finance.yahoo.com/news/arrowhead-pharmaceuticals-participate-upcoming-september-113000582.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAAJY0c6cs7v1EF8wbubC1ABUqc8xmguOuqo0xyPrSDo1Yy9cmi8ykujeD12z0F1It0l8z1zWkV3vDmvzK_9Epu2r_MYfqHY9q_VKH9eU6hhoBAC0VKqmixJMeFp5K8LtmI3NOqu6c1sIrTl0NEe0txD69Y26fZ0t_FIDYo7HVBFxL

https://www.ersnet.org/congress-and-events/congress/

RAP Price at posting: 20.0¢ Sentiment: None Disclosure: Not Held
1 Upvote

0 Great analysis

Reply

Top Stories

COB

Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

OJC

SPC to merge with Original Juice Co and Nature One Dairy